Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Clinical Chemistry

Beyond intended use: PSA, hCG as tumor markers

June 2025—At Corewell Health William Beaumont University Hospital in Royal Oak, Mich., the PSA test volume for men ages 40 to 49 is significant—about 150 samples per month, or 10 percent of the laboratory’s total PSA testing volume. But with no PSA assay approved for men under age 50, the laboratory set out to validate its Abbott Architect assay for this age group as a laboratory-developed test. Qian (Katie) Sun, PhD, D(ABCC), technical director of automated chemistry and urinalysis, explained how it was done in an ADLM session last year on designing validation protocols for off-label use of tumor markers in diverse patient populations. She also spoke about the use of hCG immunoassays as a tumor marker in gestational trophoblastic disease and select germ cell tumors.

Focus on instruments: scalability, timelines, and IT

June 2025—Chemistry and immunoassay analyzers—the customer input that shapes their development and the laboratory acquisition process and timeline. That and more, including the IT obstacles and solutions, were the focus of a roundtable, led by CAP TODAY publisher Bob McGonnagle. He spoke with Moira Larsen, MD, MBA, of MedStar Health; Joe Baker of Baylor Scott & White; and representatives of Beckman Coulter, Roche, and Siemens Healthineers. Read about their April 15 online conversation.

Misses, hits in urine drug test interpretation

May 2025—When a physician or health care professional isn’t sure how to interpret a urine drug test result, Christine Snozek, PhD, codirector of clinical chemistry at Mayo Clinic in Arizona, always hopes they’ll call the laboratory for help—especially if the alternative is paging Dr. Google.

In chemistry and more, what to know about new checklist edition

February 2025—In the 2024 accreditation program checklist edition, released Dec. 26, are new and revised requirements for chemistry, diagnostic immunology, and flow cytometry laboratories. Two of the flow cytometry requirements are now also in the anatomic pathology checklist.

Rethinking maternal AFP race adjustments

November 2024—David Grenache, PhD, D(ABCC), chief scientific officer of TriCore, is breaking no new ground when he considers the maternal serum alpha-fetoprotein test and says, “A screening test is designed to put people into one of two camps.” No scientific advances there. But the reverberations of this particular screening test have landed patients and physicians in complicated situations of late. The obvious divide is to identify increased risk of fetal abnormalities, including open neural tube defects. But the test has historically incorporated a race adjustment for Black patients. And that adjustment—seen as a way to account for reported differences in AFP values between Black and non-Black pregnant persons—in turn has come under more scrutiny recently as physicians question whether the adjustment should continue to be used, or whether it should be dropped, à la the race adjustment for eGFR/renal function. Compared with eGFR, evaluating the race adjustment in maternal serum AFP screening is more in its infancy, Dr. Grenache says.

With eGFR in EHR, stronger clinical decision support

November 2024—In health care, information overload is hardly a novel problem. But when it comes to overlooking impaired kidney function in the electronic health record, Children’s Mercy Kansas City found a novel fix—at least for a pediatric institution. The solution, says Darcy Weidemann, MD, MHS, pediatric nephrologist at Children’s Mercy Kansas City and associate professor, University of Missouri-Kansas City School of Medicine, was to implement estimated glomerular filtration rate in the EHR.

Harm or help? Maternal AFP race adjustments

October 2024—Using a race adjustment in maternal serum alpha-fetoprotein screening has physicians sitting on the fence these days. Including race in calculating risk for open neural tube defects has been a longstanding practice in medicine. Adjusting for higher rates of AFP levels seen in Black pregnant patients, proponents say, allows this population to receive equitable care. That premise lies on one side of the fence. On the other are those who maintain the practice is suspect, even harmful, and that the routine use of a race-based adjustment should stop. With the experience of dropping raced-based adjustments to estimated glomerular filtration rates still fresh in many minds, physicians are now deciding whether to keep or drop the adjustment for maternal serum AFP, even ahead of any potential changes to guidance by groups such as the CAP. Little wonder. Because as anyone who has ever sat on a fence knows, it can easily become a shaky, even painful, perch.

 

eGFR equations in the EHR—how lab met the request

October 2024—In patients at risk for chronic kidney disease, clinical practice guidelines released this year recommend the combined creatinine and cystatin C-based estimated glomerular filtration rate over the creatinine-based eGFR when cystatin C is available. “Cystatin C isn’t perfect itself, but a combination of the two seems to hit the sweet spot,” Angela Ferguson, PhD, D(ABCC), said in a session at the ADLM meeting in July. Dr. Ferguson is associate professor at the University of Missouri-Kansas City School of Medicine and co-director of clinical chemistry, director of immunology, and director of point-of-care testing in the Department of Pathology and Laboratory Medicine, Children’s Mercy Kansas City. The guidelines were released by the Kidney Disease: Improving Global Outcomes chronic kidney disease work group.

MARKETPLACE

TRENDING